Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Jun ^a,c   Zhao, Zhong ^a   Lin, Emi ^b   Zhao, Wei ^a   Qian, Xianjuan ^a   Freire, Daniel ^a   Bilski, Amanda E ^a   Cheng, Alice ^a   Vempati, Prashant ^a   Ho, Lap ^a,c   Ono, Kenjiro ^d   Yamada, Masahito ^d   Pasinetti, Giulio M ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; FUROSEMIDE; GANGLION BLOCKING AGENT; HYDRALAZINE; IRBESARTAN; LOSARTAN; NICARDIPINE; NITRENDIPINE; PROPRANOLOL; RESERPINE; SCOPOLETIN; TRANDOLAPRIL; TRANEXAMIC ACID; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MOUSE; NERVE CELL CULTURE; NONHUMAN; PATHOGENESIS; SHORT COURSE THERAPY; AGED; AGONISTS; ANIMAL; ANIMAL EMBRYO; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; HUMAN; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PRIMARY CELL CULTURE; TRANSGENIC MOUSE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; FEMALE; HIPPOCAMPUS; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; NEURONS; PRIMARY CELL CULTURE;

EID: 84878774110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065232     Document Type: Article

References (39)

1. Cummings JL, (2004) Alzheimer's disease. N.Engl.J Med 351: 56-67.
2. Selkoe DJ, (2001) Alzheimer's Disease: Genes, Proteins, and Therapy. Physiol.Rev. 81: 741-766.
3. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
4. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, et al. (2005) Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nature Medicine 11: 556-561.
5. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, et al. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J.Neurosci. 22: 6331-6335.
6. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-7.
7. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
8. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. PNAS 95: 6448-6453.
9. Gylys KH, Fein JA, Tan AM, Cole GM, (2003) Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem 84: 1442-1451.
10. Braak H, Braak E, (1997) Staging of Alzheimer-related cortical destruction. Int.Psychogeriatr. 9Suppl 1: 257-261.
11. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, et al. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674.
12. Emilien G, Maloteaux JM, Beyreuther K, Masters CL, (2000) Alzheimer disease: mouse models pave the way for therapeutic opportunities. Arch Neurol 57: 176-181.
13. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, et al. (2011) Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 59: 1477-1483.
14. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, et al. (2002) The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med 162: 2046-2052.
15. Guo ZC, Fratiglioni L, Zhu L, Fastbom J, Winbald B, Viitanen M, (1999) Occurrence and progression of dementia in a community population aged 75 years and older- Relationship of antihypertensive medication use. Arch Neurol 56: 991-996.
16. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, et al. (2006) Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study. Arch Neurol 63: 686-692.
17. Lopez-Arrieta JM, Birks J, (2002) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 3: CD000147.
18. Hajjar I, Brown L, Mack WJ, Chui H (2012) Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series 1. Arch Neurol: 1-7.
19. Anonymous.
20. Wang J, Ho L, Chen L, Zhao Z, Zhao W, et al. (2007) Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin.Invest, 117, 3393-3402.
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science 274: 99-103.
22. Wang J, Ono K, Dickstein DL, rrieta-Cruz I, Zhao W, et al. (2010) Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol.Aging.
23. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, et al. (2009) Role of Hypertension in Aggravating Abeta Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovasc.Psychiatry Neurol 2009: 107286.
24. Morris R, (1984) Developments of a water-maze procedure for studying spatial-learning in the rat. Journal of Neuroscience Methods 11: 47-60.
25. Wang J, Ho L, Qin W, Rocher AB, Seror I, et al. (2005) Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19: 659-661.
26. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited 2. FASEB J 22: 659-661.
27. Schwabe L, Nader K, Wolf OT, Beaudry T, Pruessner JC, (2012) Neural signature of reconsolidation impairments by propranolol in humans 2. Biol Psychiatry 71: 380-386.
28. Schwabe L, Nader K, Pruessner JC, (2013) beta-Adrenergic blockade during reactivation reduces the subjective feeling of remembering associated with emotional episodic memories 1. Biol Psychol. 99: 227-32.
29. Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A, (2012) Propranolol's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis 1. J Psychiatry Neurosci 37: 120111.
30. Sano M, (2003) Current concepts in the prevention of Alzheimer's disease. Cns Spectrums 8: 846-53.
31. Cummings JL, (2004) Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis. 1: 60-9.
32. Hemming ML, Selkoe DJ, (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor 5. J Biol Chem 280: 37644-37650.
33. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. (2007) Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition 1. J Neurosci 27: 8628-8635.
34. Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM, (2010) Carvedilol Reestablishes Long-Term Potentiation in a Mouse Model of Alzheimer's Disease. J Alzheimers.Dis 21: 649-54.
35. Lacor PN, Bunie MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic Targeting by Alzheimer's-Related Amyloid {beta} Oligomers. J.Neurosci. 24: 10191-10200.
36. Lacor PN, Buniel MC, Furlow PW, Sanz Clemente A, Velasco PT, et al. (2007) A{beta} Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease. J.Neurosci. 27: 796-807.
37. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007) Natural Oligomers of the Alzheimer Amyloid-{beta} Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. J.Neurosci. 27: 2866-2875.
38. Hajjar I, Brown L, Mack WJ, Chui H (2012) Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series 1. Arch Neurol: 1-7.
39. Reagan-Shaw S, Niha M, Ahmad N, (2008) Dose translation from animal to human studies revisited 2. FASEB J 22: 659-661.